NDAINJECTIONINJECTABLE
Approved
Sep 1973
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 1h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DECADRON-LA (dexamethasone acetate) is a long-acting corticosteroid injection approved in 1973 for anti-inflammatory and immunosuppressive indications. It is administered via injection and provides sustained glucocorticoid activity. The drug works through glucocorticoid receptor binding to suppress inflammatory and immune responses.
LOE Approaching
As a legacy product approaching loss of exclusivity, this asset likely operates with a small, maintenance-focused team focused on defending market share rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on DECADRON-LA offers limited career growth potential as a legacy corticosteroid product in late decline with minimal clinical development or commercial expansion. Career value lies in operational efficiency, cost management, and defending existing market share rather than innovation or team expansion.
Brand ManagerProduct Manager
Worked on DECADRON-LA at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.